HAP Trading’s Verona Pharma VRNA Stock Holding History

HAP Trading’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-33,000	Closed	-$224K	–	921
2024 Q4	$224K	Buy	+33,000	New	+$1.24M	0.02%	297

Other funds holding VRNA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HAP Trading's VRNA Position: Q3 2023 in Review

HAP Trading sold out of Verona Pharma (VRNA) in Q3 2023, closing a stake of 43,805 shares — an estimated $926K sold.

HAP Trading first reported a position in VRNA in Q2 2023 and held it in 1 quarter. The position peaked at $926K in Q2 2023. 102 funds tracked by Wall St. Rank hold VRNA as of Q3 2023.

HAP Trading reported no remaining Verona Pharma position as of Q3 2023 after selling out during the quarter.
HAP Trading sold 43,805 Verona Pharma shares in Q3 2023, an estimated $926K.
HAP Trading first reported a position in Verona Pharma in Q2 2023 and held it in 1 quarter.
HAP Trading's Verona Pharma position peaked at $926K in Q2 2023.
102 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2023.

Based on HAP Trading's 13F filing for Q3 2023, filed 9 Nov 2023.